

5/644

1/16 #3

PTO/SB/21 (08-00)

Please type and sign (+) inside this box ☐

Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 09/920,480

Filing Date August 1, 2001

First Named Inventor Charles A. Nicolette

Group Art Unit 1644

Examiner Name Unassigned

Attorney Docket No. GZ 2063.10

RECEIVED

MAR 04 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers (for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of 70 References and return Postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement w/Form PTO-1449 | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/ Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name

Antoinette F. Konski
Michele Todd Wasmuth
McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111

Signature

Michele Todd Wasmuth

Date

February 11, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Date of Deposit: February 11, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C. 20231.

Jocelyn L. Lee
Jocelyn L. Lee

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



GZ 2063.10

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on this date: February 11, 2002.

By: Jocelyn L. Lee Name of person signing: Jocelyn L. Lee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Charles A. NICOLETTE

Serial No.: 09/920,480

Filing Date: August 1, 2001

For: MELANOMA ANTIGENIC PEPTIDES

Examiner: Not Yet Assigned

Group Art Unit: 1644

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

- ☐ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- ☒ Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

This Information Disclosure Statement is filed:

- ☐ After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to

RECEIVED
MAR 04 2002
TECH CENTER 1600/2900

charge Deposit Account No. [] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

This Information Disclosure Statement is filed:

- ☐ After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.

The undersigned certifies that:

- ☐ Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

II. Copies of the Cited Items:

- ☒ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
- ☐ Copies of only the following items listed on the attached Form PTO-1449 are enclosed: _____.
- ☐ Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. _____, filed _____ and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).
- ☐ Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

III. Concise Explanation of Relevance:

- ☒ A concise explanation of relevance of the items listed on Form PTO-1449 is not given.

- ☐ A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).

IV. Conclusion:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
2. a representation that a search has been made, other than as described above; or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

In accordance with M.P.E.P. § 2001.06(b), Applicant brings to the Patent Office's attention the following co-pending, co-owned applications: U.S. Serial Nos. 09/812,238 and 09/862,260, filed March 19, 2001 and May 21, 2001, respectively.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1189, Billing Reference No.: 19442-7229 for any additional fees required in connection with the filing of this Information Disclosure Statement. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


DATE: February 11, 2002

Respectfully submitted,

By: Michele Todd Wasmuth
Antoinette F. Konski
Registration No.: 34,202

Michele Todd Wasmuth
Registration No.: 43,239

McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111
Telephone: (650) 849-4950
Telefax: (650) 849-4800



Form PTO-1449	Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	Filing Date: August 1, 2001
	Group Art Unit: 1644	
(use several sheets if necessary)		

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	07/28/87	4,683,195	Mullis et al.			
	2.	07/28/87	4,683,202	Mullis			
	3.	06/28/88	4,754,065	Levenson et al.			
	4.	01/24/89	4,800,159	Mullis et al.			
	5.	08/08/95	5,440,013	Kahn			
	6.	11/17/98	5,837,249	Heber-Katz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	7.	08/23/95	0 668 350 A1	Nobel			
	8.	08/01/96	WO 96/23060	Cohen et al.			

OTHER DOCUMENTS


(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	9.	Al-Ramadi, B.K. et al. (1992) "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" <i>J. Immunol.</i> 155 (2):662-673.
	10.	Altman, J.D. et al. (1996) "Phenotypic analysis of antigen-specific T lymphocytes" <i>Science</i> 274 (5284):94-96.
	11.	Bakker, A.B.H. et al. (1997) "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope" <i>Int. J. Cancer</i> 70 :302-309.
	12.	Bertoni, R. et al. (1998) "Human class I supertypes and CTL repertoires extend to chimpanzees" <i>J. Immunol.</i> 161 :4447-4455.
	13.	Boczkowski, D. et al. (August, 1996) "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" <i>J. Exp. Med.</i> 184 :465-472.
	14.	Bordignon, C. et al. (September, 1989) "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" <i>PNAS USA</i> 86 :6748-6752.
	15.	Carter, B.J. (1992) "Adeno-associated virus vectors" <i>Curr. Op. Biotechnol.</i> 3 :533-539.
	16.	Caruso, A. et al. (1997) "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" <i>Cytometry</i> 27 :71-76.
	17.	Correll, P.H. et al. (November, 1989) "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" <i>PNAS USA</i> 86 :8912-8916.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449		Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: August 1, 2001	Group Art Unit: 1644
18.	Coulie, P.G. (June, 1997) "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" <i>Molec. Med. Today</i> 3:261-268.		
19.	Culver, K. et al. (April, 1991) "Lymphocytes as cellular vehicles for gene therapy in mouse and man" <i>PNAS USA</i> 88:3155-3159.		
20.	Dharanipragada, R. et al. (1992) "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" <i>Acta. Cryst. C</i> 48:1239-1241.		
21.	Dharanipragada, R. et al. (1993) "Synthetic linear and cyclic glucagon antagonists" <i>Int. J. Peptide Protein Res.</i> 42(1):68-77.		
22.	DiMaio, J. et al. (1989) "Synthesis of chiral piperazin-2-ones as model peptidomimetics" <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689.		
23.	Feltkamp, M.C.W. et al. (1995) "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" <i>Immunol. Lett.</i> 47:1-8.		
24.	Ferguson, M.A.J. et al. (1988) "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" <i>Ann. Rev. Biochem.</i> 57:285-320.		
25.	Fujihashi, K. et al. (1993) "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" <i>J. Immunol. Meth.</i> 160:181-189.		
26.	Garvey, D.S. et al. (1990) "3,4-disubstituted γ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" <i>J. Org. Chem.</i> 55(3):936-940.		
27.	Hruby, V.J. (1982) "Conformational restrictions of biologically active peptides via amino acid side chain groups" <i>Life Sciences</i> 31(3):189-199.		
28.	Hruby, V.J. et al. (1990) "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" <i>Biochem J.</i> 268:249-262.		
29.	Isakov, N. et al. (January, 1995) "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" <i>J. Exp. Med.</i> 181:375-380.		
30.	Jones, R.C.F., et al. (1988) "Amide bond isosteres: imidazolines in pseudopeptide chemistry" <i>Tetrahedron Lett.</i> 29(31):3853-3856.		
31.	Kahn, M. et al. (1989) "The incorporation of β -turn prosthetic units into merrifield solid phase peptide synthesis" <i>Tetrahedron Lett.</i> 30(18):2317-2320.		
32.	Karlsson, S. et al. (1986) "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" <i>The EMBO J.</i> 5(9):2377-2385.		
33.	Kazmierski, W. M. et al. (1991) "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of α,β -dimethyl-phenylalanine and α,β -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" <i>Tetrahedron Lett.</i> 32(41):5769-5772.		
34.	Kazmierski, W.M. et al. (1991) "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" <i>J. Am. Chem. Soc.</i> 113:2275-2283.		
35.	Kemp, D.S. et al. "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent β -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> 50:5834-5838.		
36.	Kemp, D.S. et al. (1988) "Conformational analysis of peptide-functionalized diacylaminoepindolidiones ^1H		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			



PTO/SF708 (2/92)

Sheet 3 of 4

RECEIVED
TECHNICAL CENTER 160012900
04/2002

Form PTO-1449		Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: August 1, 2001	Group Art Unit: 1644
		NMR evidence for β -sheet formation" <i>Tetrahedron Lett.</i> 29 (40):5081-5082.	
37.	Kemp, D.S. et al. (1988) "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diazacyclodeca-2, 7-dione The dilactam of L- α , γ -diaminobutyric acid and D-glutamic acid: A β -turn template" <i>Tetrahedron Lett.</i> 29 (40):5057-5060.		
38.	Kemp, D.S. et al. (1988) "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 ^{4,8}]-ridecane, 1 the preferred conformation of 1 (1= α temp-OH) and its peptide conjugates α temp-L-(Ala) _n -OR (n=1 to 4) and α -temp -L-Ala-L-Phe-Lys(ϵ Boc)-L-Lys(ϵ -Boc)-NHMe studies of templates for α -helix formation" <i>Tetrahedron Lett.</i> 29 (39):4935-4938.		
39.	Kemp, D.S. et al. (1989) "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as γ -turn templates" <i>J. Org. Chem.</i> 54 :109-115.		
40.	McGrory, W.J. et al. (1988) "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" <i>Virology</i> 163 :614-617.		
41.	Merrifield, R.B. (1967) "New approaches to the chemical synthesis of peptides" <i>Recent Progress in Hormone Res.</i> 23 :451-482.		
42.	Miyake, A. et al. (1984) "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" <i>J. Takeda Res. Labs.</i> 43 (3/4):53-76.		
43.	Mosier, D.E. et al. (March, 1993) "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" <i>PNAS. USA</i> 90 :2443-2447.		
44.	Muzyczka, N. (1992) "Use of adeno-associated virus as a general transduction vector for mammalian cells" <i>Curr. Top. Microbiol. Immunol.</i> 158 :97-129.		
45.	Nagai, U. et al. (1985) "Synthesis of a bicyclic dipeptide with the shape of β -turn central part" <i>Tetrahedron Lett.</i> 26 (5):647-650.		
46.	Nair, S. et al. (February, 1992) "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" <i>J. Exp. Med.</i> 175 :609-612.		
47.	Olson, G.L. et al. (1990) "Design and synthesis of a protein β -turn mimetic" <i>J. Am. Chem. Soc.</i> 112 :323-333.		
48.	Paglia, P. et al. (January, 1996) "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" <i>J. Exp. Med.</i> 183 :317-322.		
49.	Pardoll, D.M. (1998) "Cancer vaccines" <i>Nature Med.</i> 4 (5 Suppl.):525-531.		
50.	Parker, K.C. et al. (1992) "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" <i>J. Immunol.</i> 149 (11):3580-3587.		
51.	Parker, K.C. et al. (1995) "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> 14 :34-57.		
52.	Parkhurst, M.R. et al. (1996) "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" <i>J. Immunol.</i> 157 :2539-2548.		
53.	Rill, D.R. et al. (May 15, 1992) "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" <i>Blood</i> 79 (10):2694-2700.		
54.	Rouse, R.J.D. et al. (September, 1994) "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" <i>J. Virol.</i> 68 (9):5685-5689.		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



Form PTO-1449		Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charl s A. NICOLETTE	
(use several sheets if necessary)		Filing Date: August 1, 2001	Group Art Unit: 1644
55.	Salazar, E. et al. (2000) "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" <i>Int. J. Cancer</i> 85 :829-838.		
56.	Samanen, J. et al. (1990) "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted conformation" <i>Int. J. Peptide Protein Res.</i> 35 :501-509.		
57.	Schlesinger, S. et al. (1999) "Alphavirus vectors for gene expression and vaccines" <i>Curr Opin Biotechnol.</i> 10 (5):434-439.		
58.	Sette, A. et al. (1994) "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes" <i>J. Immunol.</i> 153 (12):5586-5592.		
59.	Shirai, M. et al. (1995) "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" <i>J. Immunol.</i> 154 :2733-2742.		
60.	Stuber, G. et al. (1995) "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" <i>Int. Immunol.</i> 7 (4):653-663.		
61.	Tan, L. et al. (1997) "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" <i>J. Immunol. Meth.</i> 209 (1):25-36.		
62.	Tanguay, S. et al. (1994) "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" <i>Lymphokine Cytokine Res.</i> 13 (4):259-263.		
63.	Valmori, D. et al. (2000) "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" <i>J. Immunol.</i> 164 (2):1125-1131.		
64.	van der Burg, S.H. et al. (1996) "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" <i>J. Immunol.</i> 156 :3308-3314.		
65.	Ware, C.F. et al. (1983) "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" <i>J. Immunol.</i> 131 (3):1312-1317.		
66.	Wilchek, M. et al. (1988) "The avidin-biotin complex in bioanalytical applications" <i>Anal. Biochem.</i> 171 :1-32.		
67.	Ying, H. et al. (July 19, 1999) "Cancer therapy using a self-replicating RNA vaccine" <i>Nat. Med.</i> 5 (7):823-827.		
68.	Zabrocki, J. et al. (1988) "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" <i>J. Am. Chem. Sci.</i> 110 :5875-5880.		
69.	Zechel, C. et al. (1991) "Synthetic glucagon antagonists and partial agonists" <i>Int. J. Pep. Protein Res.</i> 38 (2):131-138.		
70.	Zweerink, H.J. et al. (March 1, 1993) "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" <i>J. Immunol.</i> 150 (5):1763-1771.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.